Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Aurobindo Pharma makes generic medicines and the chemical ingredients inside them, selling cheap copies of drugs to patients and health systems around the world.
Aurobindo Pharma is a medicine maker. It produces generic drugs — copies of brand-name medicines whose patents have expired — along with the active ingredients that go inside pills and the sterile injectable drugs hospitals use. Its customers are pharmacies, hospitals, and health systems in India, the United States, Europe, and dozens of other countries. When a drug's patent runs out, Aurobindo can sell the same molecule under its own label, usually far cheaper than the original.
The business works because the products are commodities. Aurobindo earns money by manufacturing enormous volumes at low cost and winning contracts with distributors and governments. Being one of the world's largest makers of active pharmaceutical ingredients helps: it controls the chemistry that other pill-makers have to buy. The company is based near Hyderabad and runs a sprawling manufacturing footprint, with the United States as its single biggest market — which is both a strength and a vulnerability, since American drug pricing and regulatory inspectors have an outsized say in its fortunes. The scars are real. Over the years, the U.S. Food and Drug Administration has flagged several of Aurobindo's plants for quality problems, and warning letters or import alerts can freeze sales from a factory until fixes are made. Its injectables business — sterile liquids made in specialized facilities — has been a growth engine but also a place where manufacturing flaws hurt badly. Meanwhile, generic drug prices in the U.S. have been falling for years as competitors pile in, squeezing margins across the industry.
Aurobindo's bet is scale and breadth: make more kinds of medicines, in more forms, for more markets, so no single product or plant decides its fate. It has pushed into complex injectables, biosimilars, and specialty products, and it spends heavily on research and new factories. Most of the cash it generates goes back into building that capacity rather than into big shareholder payouts. It is a workhorse, not a show pony — a company whose profits depend on relentless efficiency, regulatory discipline, and the simple fact that someone, somewhere, will always need a cheaper version of a necessary drug.
Saved answer · last researched 12 Nov 2026